Cathepsin L Deficiency Reduces Diet-Induced Atherosclerosis in Low-Density Lipoprotein Receptor-Knockout Mice

Background— Remodeling of the arterial extracellular matrix participates importantly in atherogenesis and plaque complication. Increased expression of the elastinolytic and collagenolytic enzyme cathepsin L (Cat L) in human atherosclerotic lesions suggests its participation in these processes, a hypothesis tested here in mice. Methods and Results— We generated Cat L and low-density lipoprotein receptor (LDLr) double-deficient (LDLr−/−Cat L−/−) mice by crossbreeding Cat L-null (Cat L−/−) and LDLr-deficient (LDLr−/−) mice. After 12 and 26 weeks of a Western diet, LDLr−/−Cat L−/− mice had significantly smaller atherosclerotic lesions and lipid cores compared with littermate control LDLr−/−Cat L+/− and LDLr−/−Cat L+/+ mice. In addition, lesions from the compound mutant mice showed significantly reduced levels of collagen, medial elastin degradation, CD4+ T cells, macrophages, and smooth muscle cells. Mechanistic studies showed that Cat L contributes to the degradation of extracellular matrix elastin and collagen by aortic smooth muscle cells. Smooth muscle cells from LDLr−/−Cat L−/− mice or those treated with a Cat L-selective inhibitor demonstrated significantly less degradation of elastin and collagen and delayed transmigration through elastin in vitro. Cat L deficiency also significantly impaired monocyte and T-lymphocyte transmigration through a collagen matrix in vitro, suggesting that blood-borne leukocyte penetration through the arterial basement membrane requires Cat L. Cysteine protease active site labeling demonstrated that Cat L deficiency did not affect the activity of other atherosclerosis-associated cathepsins in aortic smooth muscle cells and monocytes. Conclusions— Cat L directly participates in atherosclerosis by degrading elastin and collagen and regulates blood-borne leukocyte transmigration and lesion progression.

[1]  P. Libby,et al.  Lysosomal Cysteine Proteases in Atherosclerosis , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[2]  Y. Ru,et al.  Potent and Selective Cathepsin L Inhibitors Do Not Inhibit Human Osteoclast Resorption in Vitro * , 2001, The Journal of Biological Chemistry.

[3]  S. Stevanović,et al.  Cathepsin V is involved in the degradation of invariant chain in human thymus and is overexpressed in myasthenia gravis. , 2003, The Journal of clinical investigation.

[4]  Rebecca A. Roberts Lysosomal cysteine proteases: structure, function and inhibition of cathepsins. , 2005, Drug news & perspectives.

[5]  P. Libby,et al.  Cathepsin L expression and regulation in human abdominal aortic aneurysm, atherosclerosis, and vascular cells. , 2006, Atherosclerosis.

[6]  A. Rudensky,et al.  Cathepsin L: critical role in Ii degradation and CD4 T cell selection in the thymus. , 1998, Science.

[7]  P. Libby,et al.  Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. , 1998, The Journal of clinical investigation.

[8]  P. Wolters,et al.  Mast cell expression of gelatinases A and B is regulated by kit ligand and TGF-beta. , 1999, Journal of immunology.

[9]  I. van der Made,et al.  Disruption of the Cathepsin K Gene Reduces Atherosclerosis Progression and Induces Plaque Fibrosis but Accelerates Macrophage Foam Cell Formation , 2005, Circulation.

[10]  P. Libby,et al.  Deficiency of the Cysteine Protease Cathepsin S Impairs Microvessel Growth , 2003, Circulation research.

[11]  A. Asikainen,et al.  Collagen degradation by interleukin-1beta-stimulated gingival fibroblasts is accompanied by release and activation of multiple matrix metalloproteinases and cysteine proteinases. , 2006, Oral diseases.

[12]  Z. Galis,et al.  Targeted Disruption of the Matrix Metalloproteinase-9 Gene Impairs Smooth Muscle Cell Migration and Geometrical Arterial Remodeling , 2002, Circulation research.

[13]  G. Shi Cathepsins: novel drug targets for cardiovascular diseases? , 2005, Future cardiology.

[14]  H. Chapman,et al.  Emerging roles for cysteine proteases in human biology. , 1997, Annual review of physiology.

[15]  M. Davies,et al.  Plasminogen activator system and vascular disease. , 2006, Current vascular pharmacology.

[16]  R. Ménard,et al.  Family C1 Cysteine Proteases: Biological Diversity or Redundancy? , 2003, Biological chemistry.

[17]  A. Newby,et al.  Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. , 2005, Physiological reviews.

[18]  D. Hanahan,et al.  Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. , 2006, Genes & development.

[19]  M. Mäyränpää,et al.  Cysteine Protease Cathepsin F Is Expressed in Human Atherosclerotic Lesions, Is Secreted by Cultured Macrophages, and Modifies Low Density Lipoprotein Particles in Vitro* , 2004, Journal of Biological Chemistry.

[20]  Christoph Peters,et al.  Dilated cardiomyopathy in mice deficient for the lysosomal cysteine peptidase cathepsin L , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[21]  T. Betsuyaku,et al.  Cysteine proteinases and cystatin C in bronchoalveolar lavage fluid from subjects with subclinical emphysema. , 1998, The European respiratory journal.

[22]  Matthew Bogyo,et al.  Cathepsin V, a Novel and Potent Elastolytic Activity Expressed in Activated Macrophages* , 2004, Journal of Biological Chemistry.

[23]  P. Libby,et al.  Cystatin C Deficiency Increases Elastic Lamina Degradation and Aortic Dilatation in Apolipoprotein E–Null Mice , 2005, Circulation research.

[24]  Sheila J. Jones,et al.  Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Christine M. Miller,et al.  CCL11 (Eotaxin) Induces CCR3-Dependent Smooth Muscle Cell Migration , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[26]  A. Mcnicol,et al.  Organisation of basement membrane components in the human adult and fetal pituitary gland and in pituitary adenomas , 1997, Virchows Archiv.

[27]  P. Libby,et al.  Reduction of atherosclerosis in mice by inhibition of CD40 signalling , 1998, Nature.

[28]  T. Murohara,et al.  Localization of Cysteine Protease, Cathepsin S, to the Surface of Vascular Smooth Muscle Cells by Association with Integrin ανβ3 , 2006 .

[29]  R. Maciewicz,et al.  Cathepsin L‐deficient mice exhibit abnormal skin and bone development and show increased resistance to osteoporosis following ovariectomy , 2004, International journal of experimental pathology.

[30]  J. Guénet,et al.  Impaired hair follicle morphogenesis and cycling with abnormal epidermal differentiation in nackt mice, a cathepsin L-deficient mutation. , 2002, The American journal of pathology.

[31]  S. Lazarus,et al.  Dog mastocytoma cells secrete a 92-kD gelatinase activated extracellularly by mast cell chymase. , 1996, The Journal of clinical investigation.

[32]  S. Shapiro,et al.  Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. , 2000, The Journal of clinical investigation.

[33]  S. Weiss,et al.  Molecular cloning of human cathepsin O, a novel endoproteinase and homologue of rabbit OC2 , 1995, FEBS letters.

[34]  John H. Zhang,et al.  Cathepsin and Calpain Inhibitor E64d Attenuates Matrix Metalloproteinase-9 Activity After Focal Cerebral Ischemia in Rats , 2006, Stroke.

[35]  A. Luttun,et al.  Loss of Matrix Metalloproteinase-9 or Matrix Metalloproteinase-12 Protects Apolipoprotein E–Deficient Mice Against Atherosclerotic Media Destruction but Differentially Affects Plaque Growth , 2004, Circulation.

[36]  P. Libby,et al.  Low-Density Lipoprotein Receptor-Deficient Mice Macrophage Migration Inhibitory Factor Deficiency Impairs Atherosclerosis in , 2022 .

[37]  G. Dranoff,et al.  Cathepsin S required for normal MHC class II peptide loading and germinal center development. , 1999, Immunity.

[38]  Makoto Naito,et al.  Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice. , 2003, The Journal of clinical investigation.

[39]  T. Murohara,et al.  Localization of cysteine protease, cathepsin S, to the surface of vascular smooth muscle cells by association with integrin alphanubeta3. , 2006, The American journal of pathology.

[40]  P. Kovanen,et al.  Cathepsins F and S block HDL3-induced cholesterol efflux from macrophage foam cells. , 2003, Biochemical and biophysical research communications.

[41]  D. Rich,et al.  Molecular cloning and expression of human alveolar macrophage cathepsin S, an elastinolytic cysteine protease. , 1992, The Journal of biological chemistry.

[42]  B. Ma,et al.  Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-dependent emphysema. , 2000, The Journal of clinical investigation.

[43]  E. Vuorio,et al.  Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio. , 2005, Bone.